Abstract: In recent years, immune checkpoint inhibitors (ICIs) have shown good efficacy and safety in the treatment of several malignant tumors. Five ICIs have been approved by the U.S. FDA for the treatment of urothelial carcinoma. The NCCN guidelines have also incorporated these five ICIs into treatment regimens for patients with locally advanced or metastatic urothelial carcinoma (UC). Although the safety and survival benefits of immunotherapy are encouraging, screening of patients who can benefit is a major challenge. This article reviews the research progress in ICIs for the treatment of UC.